Guggenheim Downgrades Allogene Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Michael Schmidt has downgraded Allogene Therapeutics (NASDAQ:ALLO) from Buy to Neutral, indicating a change in the firm's outlook on the company's stock.
January 05, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim's downgrade of Allogene Therapeutics from Buy to Neutral suggests a more cautious view on the stock's near-term performance.
Downgrades by analysts can lead to a negative perception among investors, potentially causing short-term price stagnation or decline. However, the change to Neutral indicates a lack of strong negative catalysts, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100